Lead Product(s): Small interfering RNA
Therapeutic Area: Cardiology/Vascular Diseases
Highest Development Status: Phase I Product Type: Gene therapy
Partner/Sponsor/Collaborator: AstraZeneca PLC
Deal Size: $2,080.0 million Upfront Cash: $60.0 million
Deal Type: Collaboration March 26, 2020
Companies working together to deliver siRNA molecules to liver, breast, lung and other tissues. Within the first three years of the agreement the parties anticipate starting work on five targets.